4.0 Article

The Hematopoietic Cell-Specific Rho GTPase Inhibitor ARHGDIB/D4GDI Limits HIV Type 1 Replication

Journal

AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 28, Issue 8, Pages 913-922

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/aid.2011.0180

Keywords

-

Funding

  1. Japan Human Science Foundation
  2. Japanese Ministry of Health, Labor and Welfare (Research on HIV/AIDS)
  3. Japanese Ministry of Education, Culture, Sports, Science and Technology (Priority Areas Matrix of Infection Phenomena) [18073008]
  4. Grants-in-Aid for Scientific Research [18073008, 22790430, 23659229, 23790500, 24115008, 21390137] Funding Source: KAKEN

Ask authors/readers for more resources

Rho GTPases are able to influence the replication of human immunodeficiency virus type 1 (HIV-1). However, little is known about the regulation of HIV-1 replication by guanine nucleotide dissociation inhibitors (GDIs), one of the three major regulators of the Rho GTPase activation cycle. From a T cell-based cDNA library screening, ARHGDIB/RhoGDI beta, a hematopoietic lineage-specific GDI family protein, was identified as a negative regulator of HIV-1 replication. Up-regulation of ARHGDIB attenuated the replication of HIV-1 in multiple T cell lines. The results showed that (1) a significant portion of RhoA and Rac1, but not Cdc42, exists in the GTP-bound active form under steady-state conditions, (2) ectopic ARHGDIB expression reduced the F-actin content and the active forms of both RhoA and Rac1, and (3) HIV-1 infection was attenuated by either ectopic expression of ARHGDIB or inhibition of the RhoA signal cascade at the HIV-1 Env-dependent early phase of the viral life cycle. This is in good agreement with the previous finding that RhoA and Rac1 promote HIV-1 entry by increasing the efficiency of receptor clustering and virus-cell membrane fusion. In conclusion, the ARHGDIB is a lymphoid-specific intrinsic negative regulator of HIV-1 replication that acts by simultaneously inhibiting RhoA and Rac1 functions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available